REVLIMID® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

REVLIMID Videos and Perspectives

Watch a Video on the DRd Combination


Hear Dr. Davies, a multiple myeloma specialist at NYU Langone Health, talk about treating newly diagnosed MM patients ineligible for a stem cell transplant with REVLIMID + dex + dara (DRd).

Watch a Video on REVLIMID® maintenance Therapy for MM

REVLIMID Maintenance Post Auto-HSCT

Dr. Randolph, a hematologist/
oncologist at the Hollings Cancer Center, discusses data that supports his use of REVLIMID as maintenance therapy after a transplant.

Watch a Video on REVLIMID Continuous Treatment

Continuous Therapy for NSCT NDMM

Dr. Landau, a hematologist/
oncologist at Orlando Health UF Health Cancer Center, shares how continuous therapy fits into his treatment approach for his patients with multiple myeloma, even when they have a complete response.

Watch a Video on the MOA of REVLIMID®

Mechanism of Action

Learn about the immunomodulatory, tumoricidal, and antiangiogenic properties of lenalidomide.

Information about DRd does not appear in the REVLIMID full Prescribing Information.
Please see the daratumumab full Prescribing Information and Important Safety
Information at

See more resources


REVLIMID is the most prescribed NDMM therapy.3*

  • *Claims data 07/2018 - 06/2021. Source: PrecisionIQ Data
    © 2021, IntrinsiQ Specialty Solutions, Inc. All rights reserved.

Is your patient progressing on REVLIMID?

Now is the time for a different IMiD®

Learn More


The only FDA-approved maintenance therapy post auto-HSCT.1

View Maintenance Therapy Dose Modifications for Adverse Events


REVLIMID can be used in all levels of renal function.1

Adjustments to the starting dose of REVLIMID are recommended to provide appropriate drug exposure in patients with renal impairment.1

Renal Dosing in NSCT NDMM Renal Dosing for Maintenance Therapy
Bristol Myers SquibbTM Access Support® Site

BMS Access Support® can provide patient access and reimbursement assistance.

How BMS Access Support May Help

  • auto-HSCT, autologous hematopoietic stem cell transplantation; dex, dexamethasone; dara, daratumumab; NDMM, newly diagnosed multiple myeloma; NSCT, non-stem cell transplant.

References: 1. REVLIMID [package insert]. Summit, NJ: Celgene Corp. 2. Daratumumab [package insert]. Horsham, PA: Janssen Biotech, Inc. 3. Data on file. Celgene Corp; 2020.